Every 424B that Moleculin Biotech, Inc. (MBRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MBRX filings page.
Moleculin Biotech, Inc. (MBRX) is increasing the capacity of its existing at-the-market common stock program under its At The Market Offering Agreement with Roth Capital Partners to allow sales of up to $19,700,000 of common stock from and after August 21, 2026, not including shares previously sold. This supplements earlier ATM capacities of $6,500,000 set in July 2025 and $8,200,000 set in December 2025. As of this supplement, Moleculin has sold 486,775 shares for aggregate gross sales of $1,890,241 under the ATM program. The company’s common stock trades on the Nasdaq Capital Market under the symbol MBRX, with a last reported sale price of $0.5906 per share on August 20, 2026. Public float is approximately $64,852,256 based on 19,477,380 outstanding shares, of which 1,311,482 are held by affiliates, and Moleculin states it is subject to the one‑third public float limit for primary offerings under General Instruction I.B.6 of Form S‑3.
Moleculin Biotech, Inc. is conducting a reasonable best efforts public offering of up to 11,088,334 shares of common stock at $0.75 per share together with 37,130,001 Series I common warrants, plus up to 1,288,333 pre-funded warrants offered in lieu of shares for certain large investors. Each share or pre-funded warrant is sold with three common warrants, each exercisable at $0.75 for five years, with anti-dilution down to a $0.15 floor. Maximum gross proceeds are $9.28 million, with estimated net proceeds of about $8.5 million, before any warrant exercises. The company plans to use the proceeds primarily to advance its lead drug candidate Annamycin in the pivotal Phase 2/3 MIRACLE trial for relapsed/refractory AML and for working capital. The offering has no minimum, no escrow, and may close with reduced proceeds, increasing financing risk and dilution. Common shares outstanding are expected to rise from 7,100,713 to 18,189,047 (or 19,477,380 if all pre-funded warrants are exercised), excluding any exercise of the new common warrants.
Moleculin Biotech, Inc. is registering up to 6,367,956 shares of common stock for resale, consisting of shares issuable upon exercise of inducement warrants with an exercise price of $2.3976 per share.
The shares are being registered for the benefit of the selling stockholders and the company will not receive proceeds from resale; the company would receive proceeds only if the warrants are exercised for cash, which at full cash exercise at the initial exercise price would yield gross proceeds of $15.3M. The registration covers shares issuable upon exercise subject to holder-level Beneficial Ownership Limitations of 4.99% or 9.99% (holder election). Shares outstanding were 5,336,350 as of March 11, 2026.